<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25926">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769247</url>
  </required_header>
  <id_info>
    <org_study_id>384645-5</org_study_id>
    <nct_id>NCT02769247</nct_id>
  </id_info>
  <brief_title>Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion</brief_title>
  <official_title>Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed National Military Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of intrauterine lidocaine and oral naproxen sodium on discomfort and
      pain of patients undergoing intrauterine device insertion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study with women that will be
      recruited from our outpatient obstetrics and gynecology clinic. Women desiring intrauterine
      device insertion will be invited to participate.

      The investigators plan to recruit women desiring intrauterine device insertion into one of
      four groups: A: placebo/normal saline infusion; B: placebo/lidocaine infusion; C: Saline
      infusion/ naproxen; D: lidocaine infusion/ naproxen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain control with IUD insertion</measure>
    <time_frame>within 30 minutes after IUD insertion</time_frame>
    <description>visual analog scale (0-10) as assessed by patient within 30 minutes after IUD insertion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician perceived pain control during IUD insertion</measure>
    <time_frame>within 30 minutes after IUD insertion</time_frame>
    <description>visual analog scale (0-10) as assessed by physician within 30 minutes after IUD insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with IUD</measure>
    <time_frame>30 days post insertion</time_frame>
    <description>Patient satisfaction as rated on a 1-5 scale 30 days post insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty IUD insertion</measure>
    <time_frame>within 30 minutes of IUD insertion</time_frame>
    <description>as rated by the physician on a scale of 0-3 within 30 minutes of IUD insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breastfeeding/postpartum</measure>
    <time_frame>within 30 minutes of IUD insertion</time_frame>
    <description>discern if different perceived pain between recently postpartum, currently breastfeeding women and women who have not recently delivered as assessed by visual analog scale 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perceived pain 30 days post insertion</measure>
    <time_frame>30 days post IUD insertion</time_frame>
    <description>survey patient 30 days later to determine her recollection of pain during insertion (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paragard vs mirena IUD</measure>
    <time_frame>visual analog scale as assessed by patient and physician both within 30 minutes post insertion and 30 days post insertion</time_frame>
    <description>difference in pain ratings during IUD insertion as assessed by visual analog scale by both patient (0-10) and physician (0-3) within 30 minutes post insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paragard vs Mirena IUD pain medication use</measure>
    <time_frame>30 days post insertion</time_frame>
    <description>Patient's recall of self administered pain medication within 24 hours after IUD insertion as reported 30 days post insertion</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Contraception</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen/Normal saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive naproxen and intrauterine normal saline prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral medication/Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen/Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Oral naproxen vs placebo</description>
    <arm_group_label>Naproxen/Normal saline</arm_group_label>
    <arm_group_label>Naproxen/Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Intrauterine lidocaine vs normal saline</description>
    <arm_group_label>Placebo oral medication/Lidocaine</arm_group_label>
    <arm_group_label>Naproxen/Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>either normal saline or empty oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Naproxen/Normal saline</arm_group_label>
    <arm_group_label>Placebo oral medication/Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DEERS-eligible reproductive age women (i.e. Tricare beneficiaries)

          -  age 18 years and older

          -  desiring Paragard or Mirena intrauterine device insertion

        Exclusion Criteria:

          -  Current pregnancy

          -  cervical stenosis

          -  severe medical illness

          -  known allergy or sensitivity to lidocaine or naproxen

          -  peptic ulcer disease

          -  current pelvic inflammatory disease

          -  patients with known renal insufficiency

          -  patients using chronic NSAIDs or on chronic pain medication

          -  women desiring Skyla IUD insertion will also be excluded due to infrequency of
             insertions at WRNMMC
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Dunlow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WRNMMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shana Miles, MD, PhD</last_name>
    <phone>301 400 2433</phone>
    <email>shana.miles.1@us.af.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Dunlow, MD</last_name>
    <phone>301 400 2433</phone>
    <email>susan.g.dunlow.civ@mail.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shana M Miles, MD, PhD</last_name>
      <phone>301-400-2433</phone>
      <email>shana.miles.1@us.af.mil</email>
    </contact>
    <contact_backup>
      <last_name>Susan G Dunlow, MD</last_name>
      <phone>301 400 2433</phone>
      <email>susan.g.dunlow.civ@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Shana M Miles, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan G Dunlow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katerine Shvartsman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 29, 2016</lastchanged_date>
  <firstreceived_date>May 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>naproxen</keyword>
  <keyword>lidocaine</keyword>
  <keyword>intrauterine device</keyword>
  <keyword>IUD</keyword>
  <keyword>pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
